PT-141

What it is

PT-141, known medically as Bremelanotide, is a synthetic peptide developed from Melanotan II. While it was originally being researched as a sunless tanning agent, scientists noticed a "side effect" of increased sexual arousal in both men and women. This discovery shifted its development entirely toward sexual health.

Unlike most treatments for sexual dysfunction (like Viagra or Cialis) which focus on blood flow, PT-141 is a melanocortin receptor agonist. This means it works directly on the nervous system. It was FDA-approved in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

What it does

PT-141 works by activating receptors in the hypothalamus, the part of the brain that regulates "libido" or sexual desire. By working on the brain's signaling pathways, it can help trigger arousal even when physical treatments for blood flow aren't sufficient.

Users investigate it for a wide range of sexual health concerns. Because its mechanism is distinct from PDE5 inhibitors, it is sometimes explored by men who don't respond to traditional ED medications. The effects are not "instant"—they typically peak 2 to 4 hours after administration and can last for up to 24 hours.

What the evidence says

The evidence for PT-141 is strong, particularly for women. Two large Phase 3 clinical trials (RECONNECT) demonstrated that it significantly increased sexual desire and decreased the distress associated with low desire. For men, several studies have shown it can effectively induce erections, though it is not yet FDA-approved specifically for male erectile dysfunction.

The biggest limitation discovered in trials is that it doesn't work for everyone—about 25% of participants in the female trials did not see a significant change. However, for those it does work for, the effect is often reported as very reliable.

What it costs

A box of four Vyleesi auto-injectors can cost over $800 without insurance, though many patients pay less through specialty pharmacy programs. In the research community, a 10mg vial of PT-141 typically costs between $40 and $65.

Side effects and risks

The most frequent side effect is nausea, which affects about 40% of users. This is often accompanied by flushing and a temporary increase in blood pressure. Because of the blood pressure effect, it is generally not recommended for people with uncontrolled hypertension or heart disease.

PT-141 retains its FDA-approved status as Vyleesi. Compounded versions exist but fall under the broader peptide compounding scrutiny that intensified in 2025–2026.

Where users source it

For women, the safest route is a prescription for Vyleesi. For others, it is sourced through research peptide vendors. Because PT-141 is a potent central nervous system agent, we urge caution regarding dosing and frequency to avoid long-term desensitization of the receptors.

Sources

• Kingsberg SA, et al. (2019). "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder." Obstetrics & Gynecology. PMID 31135766
• FDA. (2019). "FDA approves new treatment for hypoactive sexual desire disorder in women."
• Get Peptide Clarity. (April 2026). Regulatory Tracker.